Q1 2026 Management View Martin J. Schroeter, Chairman and CEO, highlighted significant progress on strategic initiatives, ...

Kyndryl Holdings (NYSE:KD) shares sank 16% during early market trading on Tuesday after its first quarter fiscal 2026 financial results demonstrated a slight revenue decline in constant currency.

Shares of Kyndryl sank after the company recorded flat revenue in the latest completed quarter, missing analyst targets. The stock was down 19% at $29.82 in early trading. Shares are now in negative ...

Despite all of the positivity mentioned by Schroeter, it didn’t mask the fact that the company’s guidance came up short of ...

Vertex Pharmaceuticals (VRTX) stock is sliding after the company said it won't advance its pain treatment into the next phase ...

Kyndryl Holdings' first-quarter profit soared more than five-fold, the company said on Monday, as the former IBM unit's renegotiation of contracts helped improve margins on its services.

Kyndryl reaffirmed its full-year outlook and said its latest results keep it on track to meet long-term targets.

Within the next 20 months, the drag from contracts signed from when Kyndryl was part of IBM will be negligible, Kyndryl ...

A number of stocks fell in the afternoon session after a surprisingly weak U.S. jobs report was released, fueling concerns ...

Kyndryl (NYSE: KD), a leading provider of mission-critical enterprise technology services, today released financial results ...

The company reported adjusted pretax income of $128 million, a 39% increase from the prior-year period, while adjusted EBITDA rose 16% YoY to $647 million. Kyndryl’s hyperscaler-related revenue grew ...

Hims & Hers Health posted higher profit and revenue in the second quarter, and the company backed its full-year outlook. In the current quarter, the telehealth-consultation platform forecast revenue ...